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ABSTRACT
Purpose: The reliability of the International Prostate Symptom Score (I-PSS) was tested in 
patients with lower urinary tract symptoms and/or benign prostatic hyperplasia.
Materials and Methods: A total of 71 consecutive men with benign prostatic hyperplasia and/or 
lower urinary tract symptoms was asked to complete the I-PSS at baseline and 8 weeks later. At 
the second visit the physician also completed the I-PSS according to the complaints of the patient. 
Variability between both scores was evaluated by calculation of duplo errors and results were 
compared to the clinical data.
Results: A considerable variability existed between the I-PSS results obtained at baseline and 
8 weeks. The duplo error was 4.3. In a regression analysis of I-PSS, including all clinical 
parameters, only free flow had some predictive value for I-PSS outcomes.
Conclusions: It is important to consider the variability of the I-PSS score when making 
decisions concerning treatment.
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Benign prostatic hyperplasia (BPH) is a common condition 
among elderly men.1 Histologically, BPH has been reported 
in 50% of all men by age 60 years, and in nearly 100% of men 
older than 80 years.2 BPH impacts significantly on quality of 
life for the aging man primarily by producing bothersome 
urinary symptoms. Obviously, the majority of patients seek 
medical attention because of symptoms.3 Consequently, 
symptoms have become the major focus in management of 
bladder outlet obstruction due to BPH.4 Many urologists use 
symptoms as the basis for diagnosis of outlet obstruction and 
for assessing the effects of treatment. Therefore, a number of 
symptom scores have been designed to permit a more objec­
tive and structured history of lower urinary tract symptoms 
and/or BPH.
There are several advantages in having common symptom 
scores, such as assessing the efficacy of treatment of BPH, 
and facilitating comparison of the outcomes of different treat­
ment modalities conducted at different sites and at different 
times.5 Boyarsky et al first developed such a score,6 followed 
by Madsen and Iversen,7 and Fowler et al.8 More recently, 
Hald et al developed the Danish symptom score.9 In 1992 the 
American Urological Association symptom score was re­
ported and it has been adopted by the World Health Organi­
zation as the International Prostate Symptom Score 
(I-PSS).10 The score has been integrated into the evaluation 
of patients with lower urinary tract symptoms and/or BPH, 
and has been recommended as a precise tool for diagnosis in 
these patients.11 On the other hand, little is known about the 
natural history of patients with lower urinary tract symp­
toms and/or BPH, but it appears that the course is not nec­
essarily one of deterioration. A considerable fraction of pa­
tients may show spontaneous improvement or stabilization of 
symptoms.12 Also, the individual perception about the sever­
ity of disease may vary. Therefore, it is justified to question 
whether the clinician dealing with individual patients can 
rely on 1 measurement of I-PSS to recommend therapy.
Accepted for publication December 15, 1995.
PA T IEN TS AND METHODS
A total of 71 consecutive men with BPH and/or lower 
urinary tract symptoms who were referred to our prostate 
center participated in the study. Before therapy the patients 
presented twice to our department. During visit 1 a medical 
history (including I-PSS) was obtained, and physical exami­
nation, free uroflowmetry study, post-void residual meas­
urement, biochemistry examinations (including prostate spe­
cific antigen), urinalysis, urine culture, renal ultrasound and 
transrectal ultrasonography of the prostate were performed. 
Two months (median 8 weeks) following visit 1 all patients 
underwent urodynamic investigation, including pressure- 
flow study analysis, and flexible urethrocystoscopy, and pos­
sible treatm ent options were discussed. All patients com­
pleted the I-PSS a t both visits. During visit 2 the physician 
also completed the I-PSS according to the complaints of the 
patient.
Transrectal ultrasound was performed using an ultra­
sound scanner with a 7.5 MHz. transrectal probe (multi- 
3-dimensional VRW 77 AK). The prostate was imaged from 
base to apex, documenting the presence of prostate abnor­
malities and measuring the prostate volume using the plani- 
metric method. During the same session renal ultrasound 
was performed with the same scanner in combination with 
the abdominal probe (sector AWP, 3.5 MHz.). With the same 
probe the post-void residual also was measured using the 
ellipsoid formula.
The uro dynamic evaluation was performed using an 8F 
transurethral lumen catheter with an 8F intravesical mi­
crotip pressure sensor. The digitally stored data were re­
corded with equipment developed a t our department. To ob­
tain  useful information from pressure-flow study curves it is 
necessary to relate detrusor pressure to the  corresponding 
flow. To quantify the grade of outlet obstruction the concept 
of the linear passive urethral resistance relation, connecting 
minimal urethral opening pressure with pressure a t maxi­
mum flow, was used: classes 0 and 1—no uro dynamic ob-
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Table 1. Clinical parameters and results o f  total I-PSS at visit 1 
as completed by the patients, and at visit 2 as completed by the
patients and physicians
Mean ±  SD
Pt. age (yrs.) 63 ±  9
Prostate vol. (cm.3) 43 ± 22
Maximum flow ra te  (mlVsec.) 10.9 ± 4.2
Residual vol. (ml.) 56 ± 73
Linear passive u re th ra l resistance relation 2.2 ± 1.4
I-PSS:
Visit 1 (51 pts.) 16.9 ± 5.9
Visit 2 (67 pts.) 15.6 ± 7.46
Visit 2 (68 physicians) 15.2 ± 6.41
struction, classes 2 and 3—moderate bladder outlet obstruc­
tion, and higher classes—severe obstruction.13
Systematic errors in the completion of the I-PSS were 
evaluated by calculating the mean difference of the total 
score between visits 1 and 2 as noted by the patient and 
physician. Statistical significance of these 2 mean differences 
was determined by Student’s t  test as well as by calculating 
95% confidence intervals. Random variability of the I-PSS 
was evaluated by calculation of the duplo error according to: 
V 2 (dj — d')2/2(n — 1 ), where is the difference between 
measurements 1 and 2 , d' is the systematic error and n  is the 
number of patients. When the  systematic error is 0, this 
formula reduces to: \ /2 (d i2)/2n. If the interpretation of the 
duplo error is estimated to be 4 and the I-PSS is 20 at visit 1, 
then the score might be 20 ± (2 x  4) = 12 to 28 a t visit 2 due 
to random variation alone.
The independent influence of objective parameters on the 
I-PSS was evaluated with multivariate linear regression 
models. With multiple linear regression analyses we also 
evaluated whether any of the objective parameters could 
predict a difference in the I-PSS at both visits. In these latter 
analyses the absolute differences were modeled as a depen­
dent variable.
R ESU LTS
Patient age ranged from 44 to 83 years (mean plus or 
minus standard deviation 63 ± 9). M ean prostate volume
was 43 ± 22 cm.3 (range 16 to 113), mean free maximum flow 
was 10.9 ± 4.2 ml. per second (range 1.9 to 22.0) and mean 
voided volume was 270 ± 158 ml. (range 60 to 859 ml.). 
Post-void residual ranged from 0 to 280 ml. (mean 56 ± 73) 
and mean linear passive urethral resistance relation was 2.2 
± 1 . 4  (range 0 to 5). The results of the I-PSS at visit 1 as 
completed by the patients, and at visit 2 as completed by the 
patients and physicians are shown in table 1 . There appeared 
to be no statistically significant systematic difference be­
tween the I-PSS at both visits. Patient scores at visit 1 minus 
those at visit 2 resulted in a mean difference (systematic 
error) of 1.6 points with a standard error of 0.9 and a 95% 
confidence interval of -0 .1  to 3.2. Since 0 lay in this interval 
there was no statistically significant systematic error (p =
0.07). However, when patient scores were evaluated at visit 1 
minus those at visit 2 some considerable differences were 
noted (fig. 1). Cases with higher and lower scores tend to 
skew to the right of figure 1 , indicating a somewhat lower 
I-PSS result at visit 2. Questions 1 and 4 had the highest and 
question 7 had the lowest random variation (fig. 2). The duplo 
error between visits 1 and 2 was 4.3.
Concerning patient scores minus physician scores at visit 
2, the systematic error was 0.5 with a 95% confidence inter­
val of -0 .6  to 1.6, which was not significant. Again, a signif­
icant number of patients had a different score at visit 2 as 
noted by patients and physicians, with patient scores some­
what higher than physician scores (fig. 3). Question 4 had the 
highest and question 7 had the lowest random variation.
When comparing I-PSS patient scores at visits 1 and 2 the 
correlation was 63% (Pearson test). The correlation between 
patient and physician scores at visit 2 was 77% (Pearson 
test). The duplo error between the total score as noted by the 
patient and physician at visit 2 was 3.4. In a linear regression 
analysis of I-PSS related to patient age, maximum free flow, 
post-void residual, prostate volume and linear passive ure­
thral resistance relation only free flow had some predictive 
value for I-PSS (table 2). There was a statistically significant 
inverse correlation between the standard I-PSS and free 
flow. If a patient scored 1 point higher on the maximum 
free flow scale, he scored 0.82 point lower on the I-PSS. 
Moreover, none of the objective parameters predicted a dif­
ference in the I-PSS at either visit.
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F ig . 1. Histogram for difference between patient (P) I-PSS scores at visits 1 and 2
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DISCUSSION
The most widely used symptom score in the assessment 
and followup of patients with lower urinary tract symptoms 
and BPH is the I-PSS (table 3). To rely on this questionnaire, 
it  is mandatory to evaluate test reliability. Barry et al noted 
tha t test reliability can be increased by basing decisions on 
the mean of 2 or more measurements from the same pa­
tient.14 Because symptoms can vary data to estimate within 
patient variability m ust come from repeated measures of the 
variable during a period short enough so th a t it is unlikely 
that true consistent changes in patient condition have oc­
curred.
In our study the majority of measurements were repeated 
within 8 weeks, since the waiting list for visit 2 takes that
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Fig, 3. Histogram for difference between patient (P) and physician (D) I-PSS scores at visit 2
Table 2 . Linear regression analysis on I-P SS  o f different clinical
and urodynamic parameters
ßcoeffieiunt SE p Value
Intercept 21.04 8.04 0.01
Pt. age (yrs.) 0.04 0.12 0.73
Maximum flow ra te  (ml./sec.) - 0.82 0,24 0.001
Residual vol. (ml.) -0 .0 1 0.01 0.44
Prostate vol. (cm.3) 0.04 0.05 0.35
Linear passive ure th ra l resistance relation — 1.04 2,69 0,70
The explained variance of this model is 0.22.
long. We observed a tendency for lower scores a t visit 2, 8 
weeks after visit 1 , which is difficult to explain. The learning 
effect may result in a lower score or the patient may better 
observe voiding and document it more accurately. Also, pa­
tients may believe the complaints to be more serious than 
they actually are, and they may initially be worried about 
prostate cancer and become less concerned when carcinoma 
is ruled out. Indeed, patients tend to overestimate the com­
plaints, which is illustrated by the higher score obtained by 
the patient than by the physician (table 1). In general, how­
ever, our results are within the 95% confidence intervals. 
Therefore we concluded tha t no statistically significant sys­
tematic error exists. Although we do not expect a  systematic 
error we do expect a significant random variation. In our 
study the duplo error for the difference between total I-PSS 
patient scores a t visits 1 and 2 was 4.3. A similar conclusion 
can be made when measuring the duplo error of patient and 
physician scores at visit 2 . This error was somewhat smaller 
than the duplo error of patient scores a t both visits.
The changes found in total patient I-PSS scores at both 
visits, and between patient and physician scores at visit 2 are 
presented in figure 4. If a score of more than  12 is mandatory 
for inclusion in a treatm ent protocol, then 12 patients (24%) 
did and did not comply with this requirement a t visits 1 and
2, respectively, which is significant. Therefore, we believe 
that the decision on whether to trea t the patient using symp­
tom scores as the sole criterion should be made a t an interval 
of 8 weeks. Also, we learned from a study in a large number 
of patients followed according to a watchful waiting protocol
that those without urodynamic ally proved obstruction had 
fewer complaints at 6 months of foliowup, while those with 
obstruction still had a symptom score at the same level.12 
Therefore, we should perhaps include the results of urody­
namic studies with pressure-flow study analysis to improve 
the reliability of the I-PSS results. However, in a consider­
able number of studies no significant correlation was found 
between the results of symptom scores and urodynamic stud­
ies.16 Also, in our study a regression analysis showed that the 
grade of bladder outlet obstruction (expressed by the linear 
passive urethral resistance relation result) had no predictive 
value for I-PSS.
The diagnosis of patients with BPH and/or lower urinary 
tract symptoms, and the decision to treat are based largely on 
the nature and severity of the presenting symptoms.3 During 
recent years we learned that the presenting complaints are 
not caused by a single factor but by a combination of factors. 
The recommendation that objective evaluations are optional 
may tempt clinicians to refrain from their use and, thus, only 
rely on symptoms. In view of the emerging newer and more 
complex technologies in our armamentarium ,16“19 all efforts 
must be made to obtain accurate tools for assessment and 
evaluation of patients who present with complaints. From 
our study we learned that at an interval of 8 weeks, one- 
quarter of all patients no longer complied with the inclusion 
criteria for treatment used at our department, which is in 
accordance with previous findings.14
CONCLUSIONS
We agree that the I-PSS can be an important tool in as­
sessing patient perception of the clinical problem, and should 
be used only for baseline and folio wup evaluation of these 
patients. Moreover, one must keep in mind the variability of 
the I-PSS when making decisions concerning (surgical) treat­
ment. Therefore, we recommend that at the baseline prefer­
ably 2 I-PSS questionnaires be completed and that the sec­
ond score be used as the baseline. In case of a significant 
difference in scores, a third I-PSS questionnaire should pos­
sibly be completed at an 8-week interval before deciding 
whether to treat the patient.
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Table 3. I-PSS score
Question Not atAll
Less Than 1 
Time in 5
Less Than Half 
the Time About Half the Time
More Than Half 
the Time Almost Always
1. Over the past month, how often 
have you had a sensation of not 
emptying your bladder com­
pletely after you finished uri­
nating?
0 1 2 3 4 5
2. Over the past month, how often 
have you had to urinate again 
less than two hours after you 
finished urinating?
0 1 2 3 4 5
3. Over the past month, how often 
have you found you stopped 
and started again several times 
when you urinated?
0 1 2 3 4 5
4. Over the past month, how often 
have you found it difficult to 
postpone urination?
0 1 2 3 4 5
5. Over the past month, how often 
have you had a weak urinary 
system?
0 1 2 3 4 5
6. Over the past month, how often 
have you had to push or strain 
to begin urination?
0 1 2 3
1
4 5
None 1 Time 2 Times 3 Times 4 Times 5 or More 
Times
7. Over the past month, how 
many times did you most typi­
cally get up to urinate from the 
time you went to bed at night 
until the time you got up in the 
morning?
0 1 2 3 4 5
Total I-PPS Score S =
Quality of Life Due to Urinary Symptoms
Delighted Pleased Mostly Mixed, About Mostly Unhappy Terrible
Satisfied Equality Satisfied Dissatisfied.
and Dissatisfied
1. If you were to spend the rest of 0 1 2  3 4 5 6
your life with your urinary con­
dition just the way it is now, 
how would you feel about that?
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EDITORIAL COMMENT
It is clear that many patients with BPH do not understand the 
symptom score index. The American terminology used also is not 
always understandable to some men. Moreover, the translation of 
the symptom score into another language may not be clear.
In our studies focusing on black men with BPH we found it nec­
essary to assist the patient so that he could understand each of the 
symptoms. Classification of the I-PSS by the patient was enhanced 
at visit 2 when the volunteer or nurse who presented the symptom 
score questionnaire to the patient had better interaction with the 
patient and repeated the questions, Only after the third symptom 
score presentation was the patient confident of the symptoms and a 
more reliable score was obtained.
I reviewed a previous article from Brazil in which the urologist 
interviewed natives, semi-illiterate and illiterate, who did not un­
derstand the BPH symptom score. Only after a recommended third 
evaluation of the I-PSS, which we suggested, did we believe that the 
native men would have a more complete and better understanding of 
the questions related to BPH. We believe they needed assistance at 
all 3 evaluations. We recommended that the evaluations be done 2 
months apart. Inclusion of a urodynamic evaluation also enhances 
the article.
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